The discovery that inhibition of a circadian regulator enhances autophagy-dependent cancer cell death reveals potential avenues for the development of new multifunctional anticancer agents. Further studies may elucidate novel crosstalk between circadian rhythm, metabolism, and autophagy that determines cancer cell viability.
Keywords: REV-ERB; anticancer agents; autophagy; cancer metabolism; chronotherapy; circadian clock; dual inhibitor; nuclear receptors.